Hemp Industry Sues DEA Over HHC Ban in Federal Court Challenge

Multiple hemp companies have filed federal lawsuits challenging the Drug Enforcement Administration's classification of hexahydrocannabinol (HHC) as an illegal Schedule I controlled substance, setting up a legal battle over the regulatory status of synthetic cannabinoids derived from hemp.

The DEA issued a rule in December declaring that HHC—a cannabinoid produced synthetically from cannabis plant components—falls under federal prohibition despite being marketed as a legal hemp derivative. The agency stated it had already considered the compound illegal under the Controlled Substances Act, but formalized its position through the recent regulatory action.

The lawsuits represent the latest friction point between the rapidly expanding hemp industry and federal regulators struggling to define boundaries established by the 2018 Farm Bill, which legalized hemp and its derivatives containing less than 0.3% delta-9 THC.

The Legal Arguments

The hemp companies contend that HHC should be considered a legal hemp derivative under the Farm Bill's definition. Because the compound can be synthesized from CBD—itself a legal hemp cannabinoid—the plaintiffs argue it falls within the statute's protections for "all derivatives, extracts, cannabinoids" from hemp.

But the DEA maintains that synthetically produced cannabinoids, regardless of their starting material, constitute controlled substances. The agency's position hinges on the distinction between naturally occurring hemp compounds and those created through chemical synthesis.

This interpretation has significant implications for the estimated $28 billion hemp industry, where companies have increasingly turned to alternative cannabinoids like HHC, delta-8 THC, and THC-O as legal substitutes for traditional cannabis products in states without adult-use programs.

Market Impact

HHC products have proliferated across retail shelves and online marketplaces over the past two years, with manufacturers touting the compound as producing effects similar to delta-9 THC while remaining federally legal. The market for alternative cannabinoids reached approximately $2 billion in 2023, according to industry estimates.

Several major hemp retailers have already pulled HHC products from their inventories following the DEA's announcement, while others continue sales pending the outcome of legal challenges. The uncertainty has created confusion among retailers, manufacturers, and consumers about which products remain compliant with federal law.

Trade groups including the U.S. Hemp Roundtable have expressed concern that the DEA's broad interpretation could extend beyond HHC to other hemp-derived cannabinoids, potentially undermining the entire alternative cannabinoid market that emerged post-2018.

What Happens Next

The lawsuits will likely take months or years to resolve through the federal court system. Hemp companies are seeking preliminary injunctions to prevent DEA enforcement actions while the cases proceed.

Legal experts note that courts have generally deferred to DEA's authority in classifying controlled substances, but the 2018 Farm Bill's explicit legalization of hemp derivatives creates novel legal questions. The cases could ultimately hinge on how courts interpret the relationship between the Farm Bill and the Controlled Substances Act.

Meanwhile, several states have moved to regulate or ban synthetic cannabinoids independently of federal action. Colorado, Oregon, and New York have all restricted HHC and similar compounds through state legislation, creating a patchwork of regulations that further complicates the legal landscape.

The outcome will determine whether hemp companies can continue developing and selling synthetic cannabinoids, or whether the DEA's interpretation effectively closes off this market segment despite the Farm Bill's hemp legalization provisions.

---

This article is based on original reporting by www.marijuanamoment.net.